Pharmaceutical formulation

CN118986987APending Publication Date: 2024-11-22MERCK PATENT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411103956.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-07-10
Filing Date
2020-07-08
Publication Date
2024-11-22

Smart Images

  • Figure CN118986987A_ABST
    Figure CN118986987A_ABST
Patent Text Reader

Abstract

The present invention relates to pharmaceutical formulations. The present invention relates to solid pharmaceutical formulations of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1, 6-dihydro-pyridazine-3-yl)-benzonitrile, to a process for the preparation thereof, and to the medical use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention application with patent application number 202080049753.5, application date July 8, 2020, and invention name “Pharmaceutical Preparation”.

[0002] The present invention relates to a solid pharmaceutical preparation of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile, a preparation method thereof and medical use thereof.

[0003] 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is disclosed as Example 40 in WO 2009 / 006959 A1 as a member of the family of pyridazinone derivatives which have been found to have valuable pharmacological properties. A specific salt of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is disclosed in WO 2009 / 007074 A1. It is a potent c-Met inhibitor which inhibits the enzymatic activity of c-Met tyrosine kinase. c-Met is a proto-oncogene which encodes a protein known as hepatocyte growth factor receptor (HGFR) inhibitor. Inhibition of c-Met has been shown to be a promising approach for treating cancer alone and in combination with other treatments including chemotherapy, radiation therapy and / or immunotherapy.

[0004] 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile has very low solubility in water and biorelevant media. In detail, the solubility of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile in fasted simulated intestinal fluid (FaSSIFF) is 43 μg / mL, while the solubility in fed simulated intestinal fluid (FeSSIF) is 319 μg / mL. Despite such low solubility, relatively high doses of much higher than 100 mg are required for use in therapy. At an estimated effective human dose of about 500 mg, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile has a dose / solubility ratio >10000 and can be classified as BCS IV (Amidon et al., 1995). Therefore, pharmaceutical preparations for oral administration must have high bioavailability to provide the high doses required to achieve the desired therapeutic effect. Otherwise, the pharmaceutical preparation would need to have an increased size that would not be useful for its oral administration due to its swallowability problems.

[0005] Micronization of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile improves bioavailability but causes other effects such as stickiness and very poor flow properties as well as unfavorable compaction properties, which are detrimental to the development of a robust formulation that can be produced on an industrial scale (e.g., 50,000-100,000 tablets / batch), as is required to be able to supply Phase III clinical studies as well as market supply.

[0006] In addition, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile exhibits high elasticity, which is known to be associated with poor compression properties. In fact, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile has an elasticity comparable to corn starch, which is known to have poor compaction potential due to its elasticity (Lean M. et al., Pharm Dev Technol, 2015; 20(1): 12-21). In the cited references, a classification of the properties of different pharmaceutical excipients and their use in different manufacturing methods is proposed. For corn starch, a higher risk of dry granulation technology due to high elastic recovery properties is described, making the excipient unsuitable for the manufacturing method.

[0007] Furthermore, it is known in the art that direct compression is generally only feasible for potent drugs with drug content less than 30% of the formulation (Jivraj M. et al., PSTT Vol. 3, No. 2, February 2000). Since the formulation should deliver 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile at a high dose in the range of about 500 mg, the size of the formulation is limited to make it swallowable, so a drug load higher than 30% is required.

[0008] Alternative approaches to overcome the unfavorable compaction properties of micronized 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile by using wet granulation techniques that can be used on an industrial scale have failed. For example, if micronized 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is used for fluidized bed granulation, once the fluidized bed is in place it is blown into the filter, making it impossible to obtain a pharmaceutical formulation containing such an active ingredient. Manufacturing by high shear granulation proved unsuccessful, as prototypes developed with this manufacturing technique did not show adequate in vitro dissolution results.

[0009] It is therefore an object of the present invention to provide a pharmaceutical dosage form of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile which will provide sufficient bioavailability and have a high drug load, as well as a suitable process for its manufacture.

[0010] Various attempts to provide suitable pharmaceutical formulations such as oral solutions, self-microemulsifying drug delivery systems SEDDS or SMEDDS that provide bioavailable 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile in the amounts required for its use in therapy have failed. SEDDS / SMEDDS or emulsions could not be prepared due to the low solubility of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile in the tested oils (e.g., solubility in neutral oils <5 mg / mL). Due to the relatively high dose required for therapeutic effect (about 500 mg) and the maximum dose in self-emulsifying capsule formulation (SEDDS or SMEDDS) of no more than 5 mg, the patient would have to take 100 capsules to achieve the target dose. Therefore, this route of formulation has proven to be unfeasible. Summary of the invention

[0011] The present invention relates to a solid preparation comprising micronized 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof and a filler, wherein the 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof is present in an amount of 20-80% by weight.

[0012] 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is shown below:

[0013]

[0014] As used herein, the term "about" refers to numerical values, including, for example, integers, fractions, and percentages, whether or not explicitly stated. The term "about" generally refers to a numerical range (e.g., + / - 1-3% of the value) that one of ordinary skill in the art considers to be equivalent to the value (e.g., having the same function or result). In some cases, the term "about" may include numerical values ​​rounded to the nearest significant figure.

[0015] As used herein, "a" or "an" shall mean one or more. As used herein, when used in conjunction with the word "comprising," the word "a" or "an" shall mean one or more than one. As used herein, "another" shall mean at least a second or more. In addition, unless otherwise required by context, singular terms include pluralities and plural terms include the singular.

[0016] As used herein, "%" or "percentage" refers to weight percentage (% (w / w)), unless otherwise specified herein.

[0017] The present invention further relates to a pharmaceutical preparation comprising the solid preparation, a method for preparing the solid preparation and a method for preparing the pharmaceutical preparation, and use of the solid preparation or the pharmaceutical preparation alone or in combination with radiotherapy, chemotherapy and / or immunotherapy in the treatment of cancer.

[0018] As used herein, the term "solid formulation" refers to a three-dimensional solid pharmaceutical formulation comprising an active pharmaceutical ingredient (API) and at least one pharmaceutically acceptable excipient. Preferably, the solid formulation is a compressed mixture of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile and one or more pharmaceutically acceptable excipients, the excipient being selected, for example, from a filler and optionally one or more pharmaceutically acceptable excipients. The compressed mixture can be obtained by dry granulation and is preferably present in the form of particles that may have an irregular or regular shape. The solid formulation can be processed into other pharmaceutical preparations, such as tablets, but can also be directly administered to a patient without any changes.

[0019] In addition to fillers, one or more other excipients may be present in the solid dosage form, such as binders, glidants, disintegrants and lubricants.

[0020] As used herein, the term "micronized" refers to particles that have been reduced to micron size. According to a suitable embodiment, the average particle size of micronized 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile present in the solid formulation is characterized by a d50 value in the range of 5 μm to 80 μm, preferably 5 μm to 50 μm, and more preferably 5 μm to 25 μm. Therefore, the present invention also relates to a solid formulation, wherein the average particle size of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is characterized by a d50 value in the range of 5 μm to 80 μm, preferably 5 μm to 50 μm, and more preferably 5 μm to 25 μm.

[0021] The d of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile was measured by laser diffraction on a Malvern Mastersizer 2000 (wet method using Hydro 2000S; microtray; sample amount 100 mg; stirrer speed 2200 rpm, ultrasonication 1 min, measuring time 7.5 s; shielding 10-15%). 50 The d 50 The value is the size in microns which divides the distribution in half above and half below this diameter. d50 is the median of the volume distribution and is often also designated Dv50 (or Dv0.5).

[0022] The particle size of solid dosage forms was measured by dynamic image analysis (Retsch CamSizer X2) using a brush and a pin, with a sample volume of at least 20 mL, a slit width of 4.0 mm, a dispersion pressure of 30.0 kPa, and no speed adaptation. The size of the corresponding sphere was defined, and the sample form was defined as angular particles.

[0023] The term "filler" as used herein is an agent that increases the volume of a pharmaceutical preparation by providing the amount of material required to form a solid preparation. Fillers are also used to produce desired flow properties and compression characteristics in the preparation of solid preparations and solid pharmaceutical preparations (e.g., tablets and capsule fillers). Fillers that can be used in the present invention can be sugar alcohols (e.g., sorbitol or mannitol, dulcitol, xylitol or ribitol, preferably sorbitol or mannitol, particularly preferably mannitol), sugars (e.g., glucose, fructose, mannose, lactose, sucrose or maltose, preferably lactose, sucrose or maltose, particularly preferably lactose), starches (e.g., potato starch, rice starch, corn starch or pregelatinized starch). Fillers can be present in a solid preparation according to the present invention in an amount of 20-80% (w / w), preferably 30-70% (w / w), particularly preferably 40-65% (w / w), based on the gross weight of the solid preparation.

[0024] In addition to fillers, one or more other excipients may be present in the solid dosage form, such as binders, glidants, disintegrants and lubricants.

[0025] The solid preparation of the present invention comprises 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile in an amount of 20-80% by weight, based on the total weight of the solid preparation. According to a preferred embodiment, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is present in the solid preparation in an amount of 25-70% by weight, more preferably in an amount of 3-60% by weight, and most preferably in an amount of 35-55% by weight, based on the total weight of the solid preparation. Therefore, the present invention also relates to a solid formulation, wherein 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is present in an amount of 20-80 wt %, preferably 25-70 wt %, more preferably 3-60 wt %, and most preferably 35-55 wt %, based on the total weight of the solid formulation.

[0026] Unless otherwise indicated herein, any reference to the amount, weight or weight percentage of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof should be considered to refer to the anhydrous free form of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile.

[0027] The solid formulation may contain 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile in its free base form, but may also be 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile in its pharmaceutically acceptable form. As used herein, the term "pharmaceutically acceptable" refers to that which can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable, and includes that which is acceptable for veterinary as well as human pharmaceutical use. As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable salt of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile as defined herein, as well as that having the desired pharmacological activity of the parent 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile. The term "pharmaceutically acceptable salt" includes all hydrates of the corresponding salts. Suitable salts may be acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or acid addition salts formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, methanesulfonic acid, p-toluenesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, tartaric acid, trimethylacetic acid, and the like. Particularly suitable pharmaceutically acceptable salts of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile which may be present in the solid formulation are sulfate, phosphate, methanesulfonate, benzenesulfonate, toluenesulfonate, fumarate, monohydrochloride monohydrate or maleate, preferably monohydrochloride monohydrate. Therefore, the present invention also relates to a solid pharmaceutical formulation, wherein 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is present in the form of its sulfate, phosphate, methanesulfonate, benzenesulfonate, toluenesulfonate, fumarate, monohydrochloride monohydrate or maleate, preferably monohydrochloride monohydrate.

[0028] According to a preferred embodiment of the present invention, the solid formulation comprises sugar, sugar alcohol or dicalcium phosphate as filler. According to a particularly preferred embodiment, the filler present in the solid formulation is a sugar alcohol, whereby the sugar alcohol is sorbitol and / or mannitol, preferably mannitol.

[0029] According to a further preferred embodiment of the present invention, the solid preparation comprises a binder. Therefore, the present invention also relates to a solid preparation, wherein the solid preparation further comprises a binder.

[0030] As used herein, the term "binder" refers to an agent that provides cohesion and strength for a solid formulation. Binders that can be used in the present invention are, for example, polyvinyl pyrrolidone, polyvinyl acetate, vinyl pyrrolidone-vinyl acetate copolymers, polyethylene glycol, starch paste (e.g., corn starch paste), cellulose derivatives (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose or microcrystalline cellulose, preferably microcrystalline cellulose). Therefore, the present invention also relates to solid pharmaceutical preparations, wherein the binder is polyvinyl pyrrolidone, polyvinyl acetate, vinyl pyrrolidone-vinyl acetate copolymers, polyethylene glycol, starch paste (e.g., corn starch paste), cellulose derivatives (e.g., hydroxypropyl methylcellulose, hydroxypropyl cellulose or microcrystalline cellulose, preferably microcrystalline cellulose). The binder can be present in the solid formulation according to the present invention in a ratio of 0-20% (w / w), preferably 0-10% (w / w), particularly preferably 0-5% (w / w), based on the gross weight of the solid formulation.

[0031] Solid preparations may further include lubricants. As used herein, the term "lubricant" refers to an inactive ingredient for preventing ingredients from adhering to each other when dry granulation, filling in capsules, or being compressed into tablets. Lubricants reduce the adhesion of powder to the roller surface of a roller press, and the sliding friction of the punch in the tabletting material and the die during tabletting operation, and prevent adhesion to the tablet punch. Suitable lubricants are alkaline earth metal salts of fatty acids (such as magnesium stearate or calcium stearate), fatty acids (such as stearic acid), higher fatty alcohols (such as cetyl alcohol or stearyl alcohol), fats (such as dipalmitoyl stearin, distearic acid glyceryl, stearin or dibehenic acid glyceryl), C16-C18 alkyl-substituted dicarbonic acid alkaline earth metal salts (such as sodium stearyl fumarate), hydrated vegetable oils (such as hydrated castor oil or hydrated cottonseed oil) or minerals (such as talc). Preferred lubricants are sodium stearyl fumarate, esters of glycerol and fatty acids, stearic acid or pharmaceutically acceptable salts of stearic acid and divalent cations, preferably magnesium stearate. Lubricants may be present in the solid preparation according to the present invention in an amount of 0-5% (w / w), preferably 0.1-2% (w / w), particularly preferably 0.3-1% (w / w), most preferably about 0.5% (w / w), based on the gross weight of the solid preparation.

[0032] Solid preparations may further include disintegrants. As used herein, the term "disintegrant" refers to a compound that swells and dissolves when wetted to cause tablets or particles to disintegrate to split and release active agents. Disintegrants also serve to ensure that 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazine-3-yl)-benzonitrile is in contact with a solvent (e.g., water). Disintegrants are used to disintegrate tablets or particles, etc., and therefore enhance the dissolution of solid dosage forms when in contact with a liquid dissolution medium. Suitable disintegrants include crospovidone (cross-linked polyvinyl N-pyrrolidone), carboxymethylcellulose and its salts and derivatives, such as cross-linked derivatives, such as cross-linked sodium carboxymethylcellulose (cross-linked polymer of sodium carboxymethylcellulose), sodium carboxymethyl glycolate, sodium starch glycolate, carrageenan, agar and pectin. Crospovidone and cross-linked sodium carboxymethylcellulose are particularly preferred. The disintegrant is present in the pharmaceutical preparation according to the invention in a proportion of 0-10% (w / w), preferably 0.25-5% (w / w), particularly preferably 0.5-3% (w / w), based on the total weight of the solid preparation.

[0033] The solid preparation may further include a glidant. As used herein, the term "glidant" refers to an inactive ingredient used as a flow aid that improves the flow characteristics of particles (e.g., powders or granules). In the present invention, the flow characteristics of a solid preparation or a mixture containing a solid preparation during further processing (e.g., encapsulation or tableting). Non-limiting examples of glidants for use in the present invention include colloidal silicon dioxide (Aerosil 200, Cab-O-Sil), talc, magnesium carbonate, and combinations thereof. The glidant is present in the pharmaceutical preparation according to the present invention in a ratio of 0-7.5% (w / w), preferably 0-5% (w / w), particularly preferably 0-3% (w / w), based on the gross weight of the solid preparation.

[0034] According to a suitable embodiment of the present invention, the solid preparation is in the form of particles having an average particle size characterized by a d50 value in the range of 50 μm to 1 mm, preferably 60 μm to 800 μm, and more preferably 70-600 μm. Therefore, the present invention also relates to a solid preparation, wherein the average particle size of the solid preparation is characterized by a d50 value in the range of 50 μm to 1 mm, preferably 60 μm to 800 μm, and more preferably 70-600 μm.

[0035] In order to form a solid preparation, dry granulation can be used. As used herein, the term "dry granulation" or "dry granulation" specifically refers to a granulation technique comprising at least a compaction step. In the pharmaceutical industry, two dry granulation methods are mainly used, i.e., tableting and roller pressing, both of which can be used to prepare solid preparations. Dry granulation by tableting includes a compaction step using a compression machine, which typically contains two steel punches in a steel die cavity. Granules are formed when pressure is applied to the material particles by the punches in the cavity, and the particles typically have a diameter of about 25 mm × about 10-15 mm thick, but the specific size of the tablet is not a limiting factor of the present invention. Dry granulation by using roller pressing includes a roller pressing step, in which the material particles are compacted between rotating rollers, and a subsequent grinding step to grind the compacted material into particles. In the "dry granulation" method that can be used to prepare solid preparations, liquid is not generally used and / or a drying step is not required. The term "particle" itself does not necessarily imply a particular shape, as the ultimate shape of the particle or particles will be controlled by the particular preparation method.

[0036] The present invention also provides a pharmaceutical preparation comprising a solid preparation according to the present invention. Therefore, the present invention also relates to a pharmaceutical preparation comprising said solid preparation. The solid preparation can be used as a pharmaceutical preparation without any changes, but can also be processed into other pharmaceutical preparations, such as tablets, or filled into a sachet or capsule.

[0037] Preferably, the pharmaceutical preparation is for oral administration. Therefore, the present invention also relates to a pharmaceutical preparation, which is a pharmaceutical preparation for oral administration.

[0038] Even more preferably, the pharmaceutical formulation is an immediate release formulation.Thus, the present invention further relates to a pharmaceutical formulation, which is an immediate release formulation.

[0039] In an exemplary embodiment, the pharmaceutical formulation (preferably a tablet) is characterized by a disintegration time of 30 minutes or less, such as 20 minutes or less, preferably 15 minutes or less, and more preferably 10 minutes or less. The above disintegration time is in 0.01N HCl at 37°C in a disintegration apparatus according to USP-NF <701> (USP39–NF34 p. 537; Pharmacopeial Forum: Vol. 34(1), p. 155) Disintegration measurement: The apparatus consists of a basket-rack assembly, a 1000 mL low beaker for immersion fluid, a thermostatic arrangement for heating, and a device for raising and lowering the basket in the immersion fluid. The basket-rack assembly moves vertically along its axis and consists of six open transparent tubes; the tubes are held in a vertical position by two plates. Attached to the lower surface of the lower plate is a woven stainless steel wire cloth. If specified in the individual monographs, each tube is provided with a cylindrical disk. The disk is made of a suitable transparent plastic material. One dosage unit is placed in each of the six tubes of the basket and the disk is added. The apparatus is operated using a specified medium maintained at 37±2° as the immersion fluid. At the end of the time limit or at predetermined intervals, the basket is lifted from the fluid and observed to see whether the tablet has completely disintegrated.

[0040] In a preferred embodiment, the pharmaceutical formulation according to the invention is a capsule comprising a solid formulation and optionally one or more pharmaceutically acceptable excipients. The capsule itself may be any pharmaceutically acceptable capsule, such as a hard gelatin capsule, but should preferably be readily soluble.

[0041] In an exemplary embodiment, the pharmaceutical formulation is a capsule containing a mixture consisting of 40-100% (w / w) (e.g. at least 50% (w / w), more preferably at least 70% (w / w), 80% (w / w), 90% (w / w), 95% (w / w) or 99% (w / w)) of a solid formulation according to the present invention; and 0-60% (w / w) (i.e. the remainder of the mixture (the difference from 100% (w / w)) of at least one pharmaceutically acceptable excipient preferably selected from fillers, lubricants, glidants, disintegrants and inorganic alkali metal salts, based on the total weight of all materials contained in the capsule (i.e. the total weight of the capsule minus the weight of the capsule shell).

[0042] More recently, inorganic alkali metal salts (i.e., salts composed of ions of alkali metals and anions of inorganic acids) have been found to be useful for enhancing dissolution and include sodium chloride, sodium sulfate, sodium carbonate, sodium bicarbonate, sodium phosphate, sodium dihydrogen phosphate, potassium chloride, potassium carbonate, and potassium bicarbonate. Sodium chloride is particularly preferred.

[0043] A preferred embodiment of the present invention relates to a pharmaceutical formulation which is a capsule containing 40-100% (w / w) of a solid formulation; and 0-60% (w / w) of at least one pharmaceutically acceptable excipient preferably selected from fillers, glidants, disintegrants and lubricants, based on the total weight of all materials contained in the capsule.

[0044] As will be shown by the examples, the capsule formulation may contain, for example, 100% (w / w), 99.5% (w / w), 99% (w / w), 90% (w / w), 80% (w / w), 75% (w / w), 70% (w / w), 60% (w / w) or 50% (w / w) of solid formulation, or any range encompassed by any combination of these values, based on the total weight of all materials contained in the capsule. The remainder of the filler (the difference from 100% (w / w)) is composed of at least one pharmaceutically acceptable excipient as described above.

[0045] In an exemplary embodiment, the pharmaceutical formulation is a capsule containing a filler comprising:

[0046] 50-100% (w / w) of the solid preparation according to the present invention;

[0047] 0-20% (w / w) disintegrant;

[0048] 0-50% (w / w) filler;

[0049] 0-5% (w / w) lubricant;

[0050] 0-5% (w / w) glidant;

[0051] 0-20% (w / w) of an inorganic alkali metal salt; and

[0052] One or more additional pharmaceutically acceptable excipients in a total amount of 0-20% (w / w), based on the total weight of the capsule.

[0053] In the above exemplary embodiments, the filler may be present, for example, in the range of 5-50% (w / w), or in the range of 7.5-50% (w / w), or for example in the range of 10-40% (w / w).

[0054] In the above exemplary embodiments, an inorganic alkali metal salt is preferably present and may be included in an amount of 2.5-20% (w / w), or 5-17.5% (w / w), for example, or at least 7.5% (w / w), for example about 10% (w / w) or 15% (w / w).

[0055] In a more preferred embodiment, the pharmaceutical preparation is a tablet and therefore, in addition to the pharmaceutically acceptable excipients present in the solid preparation, generally comprises at least one other pharmaceutically acceptable excipient. The at least one other pharmaceutically acceptable excipient is preferably selected from fillers, glidants, disintegrants, lubricants, inorganic alkali metal salts or combinations thereof. Therefore, the present invention also relates to a pharmaceutical preparation, which is a tablet and, in addition to the pharmaceutically acceptable excipients present in the solid preparation, optionally comprises one or more pharmaceutically acceptable excipients selected from fillers, disintegrants, glidants and lubricants.

[0056] In an exemplary embodiment, the pharmaceutical formulation is a tablet comprising a solid formulation and optionally other excipients, the tablet comprising, based on its total weight:

[0057] i) 20-80% (w / w) of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof;

[0058] ii) 10-70% (w / w) filler;

[0059] iii) 0-20% (w / w) of a binder;

[0060] iv) 0-20% (w / w) of a disintegrant;

[0061] v) 0-5% (w / w) lubricant;

[0062] vi) 0-7.5% (w / w) of a glidant; and

[0063] vii) one or more additional pharmaceutically acceptable excipients in a total amount of 0-20% (w / w).

[0064] The one or more additional pharmaceutically acceptable excipients may include one or more selected from preservatives, antioxidants, sweeteners, flavoring agents, dyes, surfactants, and wicking agents.

[0065] Many excipients can perform more than one function, depending on the other components of the pharmaceutical dosage form. For the sake of clarity, especially when calculating weight percentages, each pharmaceutically acceptable excipient to be used in the pharmaceutical formulation according to the present invention is preferably associated with only one functionality, i.e., considered as a disintegrant or a lubricant.

[0066] In another exemplary embodiment, the pharmaceutical formulation is a tablet comprising a solid formulation and optionally other excipients, the tablet comprising, based on its total weight:

[0067] i) 30-70% (w / w) of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof;

[0068] ii) 20-60% (w / w) filler;

[0069] iii) 0-10% (w / w) of a binder;

[0070] iv) 0.25-10% (w / w) of a disintegrant;

[0071] v) 0-4% (w / w) lubricant;

[0072] vi) 0-5% (w / w) of a glidant; and

[0073] vii) one or more additional pharmaceutically acceptable excipients in a total amount of 0-10% (w / w).

[0074] In a further exemplary embodiment, the pharmaceutical formulation is a tablet comprising a solid formulation and optionally other excipients, the tablet comprising, based on its total weight:

[0075] i) 35-60% (w / w) of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof;

[0076] ii) 40-60% (w / w) filler;

[0077] iii) 0-5% (w / w) of a binder;

[0078] iv) 0.5-5% (w / w) of a disintegrant;

[0079] v) 0.25-3% (w / w) lubricant;

[0080] vi) 0-2% (w / w) of a glidant; and

[0081] vii) one or more additional pharmaceutically acceptable excipients in a total amount of 0-10% (w / w).

[0082] Preferably, in those embodiments, the filler is mannitol or lactose, the binder is microcrystalline cellulose, the disintegrant is selected from crospovidone, carboxymethylcellulose and its salts and derivatives, especially croscarmellose sodium, the lubricant is selected from magnesium stearate, calcium stearate and sodium stearyl fumarate, and / or the glidant is selected from colloidal silicon dioxide and its derivatives. In particularly preferred embodiments, the filler is mannitol, the binder is microcrystalline cellulose, the disintegrant is crospovidone, the lubricant is magnesium stearate, and the glidant is colloidal silicon dioxide.

[0083] Preferably, the total amount of one or more additional pharmaceutically acceptable excipients is 0-10% (w / w), 0-7.5% (w / w), 0-5% (w / w), 0-2.5% (w / w) or 0-1% (w / w), such as 0% (w / w).

[0084] Of course, the tablets may be coated to improve taste and / or appearance, and / or to protect the tablets from external influences (e.g. moisture). Any coating should not be calculated as a total of 100% (w / w) of the pharmaceutically active ingredients and the drug substances constituting the tablets, as listed above. For film coating, macromolecular substances such as modified celluloses including hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), polymethacrylates, polyethylene glycol and zein may be used. The thickness of the coating is preferably less than 200 μm.

[0085] The present invention also provides a method for preparing a solid formulation, which comprises dry granulation, such as tableting and roller compaction, preferably roller compaction. Therefore, the present invention also relates to a method for preparing a solid formulation, the method being dry granulation, preferably roller compaction.

[0086] The term "roller compaction" or "roller compacting" refers to a process in which a powder or granules is subjected to force between two counter-rotating rollers and pressed into a solid compact or ribbon. Roll compaction can be performed using any suitable roller compactor known to the skilled person. Suitable roller compactors include, for example, the Roller Compactor from Fitzpatrick Company, USA. Chilsonator IR220 roller press. The process parameters (especially the rolling force) can be easily implemented by routine experiments based on the common knowledge of the skilled person. Suitable rolling forces can be, for example, in the range of 2-16 kN / cm, more preferably in the range of 4-12 kN / cm, and most preferably in the range of 4-8 kN / cm.

[0087] In an exemplary embodiment, the method comprises:

[0088] (a) mixing 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof with a filler and optionally one or more other pharmaceutically acceptable excipients;

[0089] (b) dry granulating the mixture prepared by step (a) to form a solid preparation; and

[0090] (c) optionally grinding.

[0091] Preferred pharmaceutically acceptable excipients for step (a) are selected from binders, disintegrants, lubricants and glidants.According to a preferred embodiment, the dry granulation method used in the process is roller compaction.

[0092] The prepared solid preparation can be used to prepare a pharmaceutical preparation, such as a tablet or capsule. An exemplary method for preparing a pharmaceutical preparation (which is a tablet containing a solid preparation) includes

[0093] (a) performing the above method to form a solid dosage form;

[0094] (b) mixing the solid formulation with one or more pharmaceutically acceptable excipients;

[0095] (c) tableting the mixture prepared by step (b); and

[0096] (d) Optionally film-coating the tablet prepared by step (c).

[0097] Tableting or compression into tablets can be carried out using conventional eccentric presses or rotary presses.

[0098] An exemplary method for preparing a pharmaceutical formulation that is a capsule containing a solid formulation comprises

[0099] (a) performing the process to form a solid dosage form;

[0100] (b) optionally mixing the solid formulation with one or more pharmaceutically acceptable excipients and optionally granulating the obtained mixture, preferably by roller compaction;

[0101] (c) filling capsules with the mixture or granules prepared in step (b) or the solid preparation prepared in step (a).

[0102] As described in the introduction above, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile has been found to exhibit valuable properties as a c-Met tyrosine kinase inhibitor and has been found to be useful in the treatment of cancer. It is currently being studied in clinical trials.

[0103] Therefore, the present invention provides a solid preparation or a pharmaceutical preparation as described above, which is used for treating cancer.

[0104] Optionally, the treatment of cancer further comprises radiotherapy. Therefore, the present invention also relates to the pharmaceutical preparation of the present invention, which is used for treating cancer, optionally together with radiotherapy. Suitable radiotherapy treatments are described in WO 2012 / 028233 A1 and are incorporated herein by reference.

[0105] Optionally, instead of or in addition to radiotherapy, the treatment of cancer may comprise chemotherapy.Thus, the present invention also relates to a pharmaceutical formulation for use in the treatment of cancer, wherein the treatment further comprises chemotherapy.

[0106] Suitable pharmaceutically active ingredients that can be combined with 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile for chemotherapy include cisplatin and etoposide or a combination thereof, to name just one example.

[0107] Optionally, the treatment of cancer may comprise immunotherapy instead of or in addition to radiotherapy and / or chemotherapy.Thus, the present invention also relates to a pharmaceutical formulation for use in the treatment of cancer, wherein the treatment further comprises immunotherapy.

[0108] Therefore, the present invention also provides a method for treating a cancer of a patient in need thereof, the method comprising administering to the patient a pharmaceutical preparation according to the present invention, optionally in combination with radiotherapy, chemotherapy or immunotherapy or any combination thereof. In an exemplary embodiment, the present invention provides a method for treating a cancer of a patient in need thereof, the cancer being selected from colon cancer, lung cancer, head and neck cancer, pancreatic cancer and histological subtypes thereof, the method comprising administering to the patient 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazine-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof in a solid preparation or pharmaceutical preparation according to the present invention, it is combined with at least one other therapeutic agent selected from etoposide and platin.

[0109] The present invention will be described below with reference to exemplary embodiments thereof, which should not be construed as limiting the present invention. DETAILED DESCRIPTION OF THE INVENTION BRIEF DESCRIPTION OF THE DRAWINGS

[0111] Figure 1 The dissolution curves of the formulation prototypes are shown (open triangles: Example A; closed circles: Example B; closed triangles: Example C; open circles: Example D), all of which contain 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile. The dissolution conditions are as follows: 900 mL of acetate buffer at pH = 4.5 with 5 mmol / L sodium chloride and 0.1% Tween 80 at 37°C using a paddle apparatus at 75 rpm.

[0112] Figure 2 The dissolution curves of Examples 12-19 in the dissolution medium (acetate buffer at pH 4.5 + 3mmol / NaCl + 0.1% Tween) are shown, showing satisfactory dissolution. Example 12: solid circles; Example 13: hollow circles; Example 14: solid triangles; Example 15: hollow triangles; Example 16: solid squares; Example 17: hollow squares; solid diamonds: Example 18; hollow diamonds: Example 19.

[0113] Figure 3 Shown is a comparison of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (black dots) and corn starch (open dots) with respect to their elastic properties.

[0114] Figure 4 Comparison of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile with different pharmaceutical fillers is shown. Black triangles: dicalcium phosphate, open circles: mannitol, open triangles: lactose, black dots: 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile.

[0115] Preformulation Examples

[0116] Example of evaluating wet granulation technology

[0117] Embodiment A)

[0118] Example A (containing 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (30.99%), lactose (32.39%), microcrystalline cellulose type 101 (23.00%), povidone 25 (3.76%), crospovidone (3.76%) was prepared by a high shear granulation method. Figure 1 The resulting granules were then sieved through a 1.0 mm sieve and subsequently blended with crospovidone (2.35%), povidone 25 (1.41%), magnesium stearate (0.94%), talc (0.94%) and silicon dioxide (0.47%) and processed on a single punch into tablets with a crushing resistance of about 125 N, a disintegration time of <10 minutes, and a total weight of about 645 mg.

[0119] Example B)

[0120] Example B (containing 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (77.29%) and starch 1500 (19.32%) was prepared by high shear granulation method Figure 1 The resulting granules were then sieved through a 1.0 mm sieve and subsequently blended with sodium carboxymethyl starch (1.93%), magnesium stearate (0.97%) and silicon dioxide (0.48%) and processed on a single punch into tablets with a crushing resistance of about 144 N, a disintegration time of <8 minutes, and a total weight of about 259 mg.

[0121] Example C)

[0122] Example C (containing 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (26.50%), lactose (4.41%), hydroxypropyl methylcellulose (1.11%) and calcium phosphate dihydrate (53.01%) was prepared by a fluidized bed granulation method selected by a person skilled in the art. Figure 1The solid triangles in the figure). The resulting granules were then sieved through a 0.8 mm sieve and subsequently blended with pregelatinized starch (9.89%), magnesium stearate (0.99%), sodium carboxymethyl starch (2.47%) and silicon dioxide (0.49%) and processed into tablets on a single punch. The tablets were then coated using a commercially available preformulated film coating mixture based on polyvinyl alcohol, wherein the coating was present at 1.13% in the entire formulation. The resulting tablets showed a crushing resistance of about 159 N, a disintegration time of <6 minutes, and a total weight of about 755 mg.

[0123] Embodiment D)

[0124] Example D (containing 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (26.66%), lactose (4.44%), hydroxypropyl methylcellulose (1.11%) and anhydrous calcium phosphate (53.31%) was prepared by a fluidized bed granulation method selected by a person skilled in the art. Figure 1 (the hollow circle in the figure).

[0125] The resulting granules were then sieved through a 0.8 mm sieve and subsequently blended with Starch 1500 (9.89%), magnesium stearate (0.99%), sodium carboxymethyl starch (1.98%) and silicon dioxide (0.49%) and processed into tablets on a single punch press to a tablet core of approximately 741.8 mg.

[0126] The tablets were then coated using a commercially available preformulated film coating mixture based on polyvinyl alcohol, wherein the coating was present at 1.13% in the entire formulation. The resulting tablets showed a crushing resistance of about 159 N, a disintegration time of <6 minutes, and a total weight of about 750 mg.

[0127] from Figure 1 As can be seen in Figure 3, tablets made with granules prepared by high shear granulation (Examples A and B) did not show satisfactory in vitro release properties. In addition, tablets made with granules prepared by fluidized bed granulation (Examples C and D) showed better in vitro release properties than the high shear granulated prototypes (Examples A and B), but they were limited in their maximum achievable drug load.

[0128] Example of evaluating the material property Young's modulus

[0129] Young's modulus is evaluated as an indication of the stiffness of the material (the higher the Young's modulus, the stiffer the material), and its measurement is thus dependent on the solid fraction complementary to the porosity (i.e., solid fraction = 1 - porosity fraction). Thus, a solid fraction of 1 indicates no porosity, i.e., no air is entrained in the solid phase. Pharmaceutically relevant solid fractions are typically in the range of 0.75-0.85. Porosity is determined by nitrogen pycnometry.

[0130] The measurements for determining the Young's modulus are carried out on a commercially available instrumented single punch press (Romaco Kilian StylOne system) with an ultrasound-assisted measuring punch. For this purpose, a pure substance is compacted between an upper punch and a lower punch, resulting in densification of the material. The speed of the ultrasound wave in the sample, which depends on the degree of densification, is recorded and used to calculate the Young's modulus of the specific substance.

[0131] For this study, the following pure materials were selected:

[0132]

[0133]

[0134] As in Figure 3 As can be seen, 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile (black dots) shows similar properties to corn starch (open dots), a substance known for its high elasticity and concomitant unfavorable compression properties. In addition, Figure 4 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile was shown to have a significantly lower Young's modulus compared to widely used pharmaceutical fillers (dicalcium phosphate, mannitol, and lactose).

[0135] Formulation Examples

[0136] Example E

[0137] Exemplary Solid Dosage Formulations

[0138] Record D as above 50 value and it is in the range of 70-530 μm.

[0139] The bulk density is determined according to DIN 53468 using a 100 mL beaker.

[0140] Embodiment 1:

[0141] Each component is weighed (batch size is 103.2kg) and sieved through a 1.0mm sieve. The blend is produced by mixing all ingredients except magnesium stearate at 12rpm for 15 minutes in a commercially available hopper blender (bin blender) (e.g., Servolift). Magnesium stearate is subsequently added, and the entire mixture is blended again at 12rpm for 5 minutes. The mixture is then transferred to a roller press for the manufacture of solid dosage forms. The roller press (Gerteis Macropactor) is operated with the following settings: compaction force 12kN / cm, gap width 2.5mm, roller speed 3.0rpm. The resulting granules are sieved through a 0.8mm sieve.

[0142] Embodiment 2:

[0143] Each component except magnesium stearate is weighed (batch size is 2.4kg) and sieved through a 1.0mm sieve. The blend is produced by mixing all the components except magnesium stearate for 15 minutes in a commercially available Turbula T50A blender. Magnesium stearate is sieved through 0.5mm and then added to the mixture, which is then blended again for 5 minutes. The mixture is then transferred to a roller press for the manufacture of solid preparations. The roller press (Alexanderwerk WP120P) is operated with the following settings: compaction force 4.0kN / cm, gap width 1.0mm, roller speed 4.0rpm. The resulting particles are sieved through a 1.0mm sieve.

[0144] Embodiment 3-8:

[0145] Each ingredient was weighed (batch size was 1.0 kg) and sieved through a 1.0 mm sieve. The blend was produced by mixing all ingredients at 12 rpm for 15 minutes in a commercially available Servolift hopper blender. The mixture was subsequently transferred to a roller compactor for the manufacture of solid dosage forms. The roller compactor (Gerteis Minipactor) was run with the following settings: compaction force 3.0 kN / cm, gap width 3.0 mm, roller speed 3.0 rpm. The resulting granules were sieved through a 1.0 mm sieve.

[0146] Embodiment 9:

[0147] Each ingredient was weighed (batch size was 33.2 kg) and sieved through a 1.0 mm sieve. The blend was produced by mixing all ingredients for 15 minutes at 12 rpm in a commercially available Servolift hopper blender. The mixture was subsequently transferred to a roller compactor for the manufacture of solid dosage forms. The roller compactor (Gerteis Macropactor) was run with the following settings: compaction force 4.5 kN / cm, gap width 3.0 mm, roller speed 3.0 rpm. The resulting granules were sieved through a 0.8 mm sieve.

[0148]

[0149]

[0150]

[0151]

[0152] Exemplary Tablet Formulations

[0153] Disintegration and friability tests are described in the European Pharmacopoeia, Edition 9.8, Chapter 2.9.1 (Disintegration) and Chapter 2.9.7 (Friability of uncoated tablets).

[0154] Embodiment 10:

[0155] The solid formulation obtained from Example 1 was blended with crospovidone for 15 minutes. Magnesium stearate was then added and the whole mixture was blended again for 5 minutes at 12 rpm. The whole mixture was tableted using a rotary tablet press, using a 18.8×9.2 mm punch, a pre-compression force of 1.6 kN and a main compression force of 17.1 kN, and a tableting speed of 20,000 units / hour.

[0156] Embodiment 11:

[0157] The solid formulation from Example 2 was blended with the ingredients for 10 minutes. The entire mixture was tableted using a single punch, using an 18×8 mm punch and a compression force of 12 kN at a tableting speed of 1860 units / hour. The disintegration time and friability values ​​were 100 N resistance to crushing.

[0158] Embodiment 12:

[0159] The solid formulation obtained from Example 3 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 15 kN, with a tableting speed of 1500 units / hour. The disintegration time and friability value were 150N for resistance to crushing.

[0160] Embodiment 13:

[0161] The solid formulation obtained from Example 4 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 21 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 110 N for resistance to crushing.

[0162] Embodiment 14:

[0163] The solid formulation from Example 5 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 17 kN, with a tableting speed of 2520 units / hour. The disintegration time and friability value were 160N for resistance to crushing.

[0164] Embodiment 15:

[0165] The solid formulation obtained from Example 6 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 17 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 150N for resistance to crushing.

[0166] Embodiment 16:

[0167] The solid formulation obtained from Example 7 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 17 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 110 N for resistance to crushing.

[0168] Embodiment 17:

[0169] The solid formulation obtained from Example 8 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 17 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 150N for resistance to crushing.

[0170] Embodiment 18:

[0171] The solid formulation obtained from Example 6 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 15 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 165N for resistance to crushing.

[0172] Embodiment 19:

[0173] The solid formulation obtained from Example 8 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 15 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 170N for resistance to crushing.

[0174] Embodiment 20:

[0175] The solid formulation obtained from Example 7 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a single punch, using a 19×9 mm punch and a compression force of 17 kN, with a tableting speed of 2460 units / hour. The disintegration time and friability value were 150N for resistance to crushing.

[0176] Embodiment 21:

[0177] The solid formulation from Example 9 was blended with all ingredients at 12 rpm for 15 minutes. The entire mixture was tableted using a rotary tablet press, using 18×9 mm punches, a pre-compression force of 5.0 kN and a main compression force of 13.0 kN, at a tableting speed of 30,000 units / hour.

[0178]

[0179]

[0180]

[0181] Exemplary Capsule Formulations

[0182] The disintegration test is described in the European Pharmacopoeia, Edition 9.8, Chapter 2.9.1 (Disintegration).

[0183] Example 22: Exemplary Capsule Formulations

[0184] HPMC capsules containing different solid formulations obtained from Examples 1-9 were prepared by mixing such formulations with other excipients as described below and filling such mixtures in capsule shells. Disintegration of the capsule formulations was less than 9 minutes.

[0185]

Claims

1. A solid formulation comprising micronized 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof and a filler, wherein 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof is present in an amount of 20% to 80% (w / w), based on the total weight of the solid formulation.

2. The solid preparation according to claim 1, wherein 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is present in the form of its sulfate, phosphate, methanesulfonate, benzenesulfonate, toluenesulfonate, fumarate, monohydrochloride monohydrate or maleate.

3. The solid formulation according to claim 1 or 2, wherein the average particle size of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile is characterized by a d50 value in the range of 5 μm to 80 μm.

4. The solid formulation according to one or more of claims 1 to 3, wherein the filler is a sugar alcohol, wherein the solid formulation further comprises a binder, and wherein the solid formulation is prepared by dry granulation.

5. The solid preparation according to claim 4, wherein the sugar alcohol is sorbitol and / or mannitol.

6. The solid preparation according to claim 4, wherein the binder is polyvinyl pyrrolidone, polyvinyl acetate, vinyl pyrrolidone-vinyl acetate copolymer, polyethylene glycol, starch paste or a cellulose derivative.

7. The solid preparation according to claim 6, wherein the binder is hydroxypropyl methylcellulose, hydroxypropyl cellulose or microcrystalline cellulose.

8. The solid formulation according to claim 1 or 2, wherein the average particle size of the solid formulation is characterized by a d50 value in the range of 50 μm to 1 mm.

9. A pharmaceutical preparation comprising the solid preparation according to any one of claims 1 to 8.

10. The pharmaceutical preparation according to claim 9, which is a pharmaceutical preparation for oral administration and / or an immediate release preparation.

11. The pharmaceutical preparation according to claim 9 or 10, which is a tablet.

12. The pharmaceutical preparation according to claim 11, wherein Based on its total weight, the tablet comprises: i) 20%-80% (w / w) of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof; ii) 10%-70% (w / w) filler; iii) 0-20% (w / w) of a binder; iv) 0-20% (w / w) of a disintegrant; v) 0-5% (w / w) lubricant; vi) 0-7.5% (w / w) of a glidant; and vii) one or more additional pharmaceutically acceptable excipients in a total amount of 0-20% (w / w); or i) 30%-70% (w / w) of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof; ii) 20%-60% (w / w) filler; iii) 0-10% (w / w) of a binder; iv) 0.25%-10% (w / w) of a disintegrant; v) 0-4% (w / w) lubricant; vi) 0-5% (w / w) of a glidant; and vii) one or more additional pharmaceutically acceptable excipients in a total amount of 0-10% (w / w); or i) 35%-60% (w / w) of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof; ii) 40%-60% (w / w) filler; iii) 0-5% (w / w) of a binder; iv) 0.5%-5% (w / w) of a disintegrant; v) 0.25%-3% (w / w) lubricant; vi) 0-2% (w / w) of a glidant; and vii) one or more additional pharmaceutically acceptable excipients in a total amount of 0-10% (w / w).

13. The pharmaceutical preparation according to claim 11, wherein one or more of the following are applicable: The filler is mannitol, The binder is microcrystalline cellulose, The disintegrant is selected from crospovidone, carboxy starch glycolate, carboxymethyl cellulose and its salts and derivatives, The lubricant is selected from magnesium stearate, calcium stearate, stearic acid, glycerol fatty acid ester and sodium stearyl fumarate, and The glidant is selected from colloidal silicon dioxide and its derivatives.

14. A method for preparing a solid preparation according to any one of claims 1 to 8, comprising: (a) mixing 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt thereof with a filler and optionally one or more other pharmaceutically acceptable excipients; (b) dry granulating the mixture prepared by step (a) to form the solid preparation; and (c) optionally grinding.

15. The method according to claim 14, wherein the dry granulation is roller compaction.

16. The method according to claim 14 or 15, further comprising: (d) mixing the solid formulation with one or more pharmaceutically acceptable excipients; (e) tableting the mixture prepared by step (d); and (f) optionally film-coating the tablet prepared by step (e).

17. Use of a solid formulation according to any one of claims 1 to 8 for the preparation of a pharmaceutical formulation according to any one of claims 9 to 13 for the treatment of cancer, optionally together with radiotherapy, chemotherapy or immunotherapy or a combination thereof.